Metsera to Present at TD Cowen's 45th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for 90 days following the event.
About Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X.
Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at investors.metsera.com. In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address.
Forward-Looking Statements
This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the Company's planned participation in and content of the Company's presentation at TD Cowen's 45th Annual Health Care Conference, including the date and time of such event. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, which are accessible on the SEC's website at www.sec.gov and the Investors section of the Company's website at investors.metsera.com. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Contact:Vicki AlbrechtMetseramedia@metsera.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
17 minutes ago
- Bloomberg
Modi Hails China Ties As The US Escalates India Criticism
Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)
Business Insider
an hour ago
- Business Insider
Guggenheim Remains a Buy on Nexstar Media Group (NXST)
In a report released today, Curry Baker from Guggenheim maintained a Buy rating on Nexstar Media Group, with a price target of $250.00. The company's shares closed today at $207.73. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Baker covers the Communication Services sector, focusing on stocks such as Liberty Media Liberty Formula One, Liberty Media Liberty Formula One, and Live Nation Entertainment. According to TipRanks, Baker has an average return of 12.4% and a 64.17% success rate on recommended stocks. In addition to Guggenheim, Nexstar Media Group also received a Buy from Barrington's Patrick Sholl in a report issued today. However, on August 15, Citi maintained a Hold rating on Nexstar Media Group (NASDAQ: NXST).
Yahoo
2 hours ago
- Yahoo
Metsera's (MTSR) Amylin Agonist Data Leads to Price Target Increase
Metsera Inc. (NASDAQ:MTSR) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 20, BofA raised the firm's price target on Metsera to $45 from $38, while keeping a Buy rating on the shares after the company announced the first round of clinical data on its amylin agonist, called MET-233i. Metsera then later released its Q2 2025 financial results in the same month. The company reported cash reserves of $530.9 million as of June 30, compared to $352.4 million as of December 31, 2024, and is expected to provide an operational runway through 2027. In Q2, Metsera reported positive Phase 1 data for MET-233i, a once-monthly amylin analog. A clinical researcher in a lab examining a new biopharmaceutical product. The company also has MET-097i, a monthly GLP-1 receptor agonist, with Phase 3 trials expected to begin in late 2025. The release of topline data from the VESPER-1 and interim data from VESPER-3 trials is anticipated in late 2025 to inform the dosing regimen for the Phase 3 trials. Additionally, Metsera's oral peptide platform, including MET-097o and MET-224o, is expected to present four-week data later in the year. Metsera Inc. (NASDAQ:MTSR) is a clinical-stage biotechnology company that develops injectable and oral nutrient-stimulated hormone analog peptides to treat obesity, overweight, and related diseases. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data
